We are live on ! Find out more
ONCE

Spark Therapeutics
ONCE

Delisted

ONCE was delisted on the 16th of December, 2019.

127 hedge funds and large institutions have $1.71B invested in Spark Therapeutics in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more call options, than puts

Call options by funds: $8.66M | Put options by funds: $3.78M

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

64% more capital inflows, than outflows

Capital inflows: $180M | Capital outflows: $110M

41% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 37

4% more funds holding

Funds holding: 122 → 127 (+5)

2.24% more ownership

Funds ownership: 89.68% → 91.92% (+2.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
127
Holders Change
+5
Holders Change %
+4.1%
% of All Funds
3.16%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
17
Increased
52
Reduced
37
Closed
10
Calls
$8.66​M
Puts
$3.78​M
Net Calls
+$4.88​M
Net Calls Change
+$1.45​M

ONCE Hedge Fund Activity: Q2 2017 in Review

127 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics (ONCE) for Q2 2017, worth a combined $1.71B — up 15% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new ONCE positions and 10 closed out — a net gain of 7 holders — while 52 added to existing stakes and 37 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $44M. The largest seller was American Century Companies, cutting an estimated $25M.

  • 127 institutional investors held Spark Therapeutics (ONCE) as of Q2 2017, up from 122 in Q1 2017.
  • Funds reported $1.71B of Spark Therapeutics stock for Q2 2017, up 15% quarter-over-quarter.
  • 17 funds opened new Spark Therapeutics positions in Q2 2017 and 10 closed out, a net change of +7 holders.
  • The largest Spark Therapeutics buyer in Q2 2017 was Citadel Advisors, an estimated $44M added.
  • The largest Spark Therapeutics seller in Q2 2017 was American Century Companies, an estimated $25M sold.

Based on aggregated 13F filings for Q2 2017.